NCT02938793View on ClinicalTrials.gov

Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors

PHASE2TerminatedINTERVENTIONAL

Enrollment

92

Participants

Timeline

Start Date

December 1, 2016

Primary Completion Date

September 17, 2025

Study Completion Date

September 17, 2025

Conditions

CancerRare Disease

Interventions

DRUG

Durvalumab

intravenous administration

DRUG

Tremelimumab

intravenous administration

Trial Locations (1)

29605

Greenville Health System Cancer Institute, Greenville

Sponsors

Collaborators (2)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

collaborator

MedImmune LLC

INDUSTRY

lead

Prisma Health-Upstate

OTHER